BR112014012815A2 - derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença - Google Patents
derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doençaInfo
- Publication number
- BR112014012815A2 BR112014012815A2 BR112014012815A BR112014012815A BR112014012815A2 BR 112014012815 A2 BR112014012815 A2 BR 112014012815A2 BR 112014012815 A BR112014012815 A BR 112014012815A BR 112014012815 A BR112014012815 A BR 112014012815A BR 112014012815 A2 BR112014012815 A2 BR 112014012815A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- oxadiazole derivatives
- disease
- trifluoromethyl oxadiazole
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
resumo patente de invenção: "derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença". a presente invenção refere-se a novos derivados de trifluormetil-oxadiazol de fórmula (i), e sais farmaceuticamente aceitáveis dos mesmos, onde todas as variáveis são conforme definidas no relatório, composições farmacêuticas dos mesmos, combinações farmacêuticas dos mesmos, e seu uso como medicamentos, particularmente para o tratamento de neurodegeneração, atrofia muscular ou diabetes/síndrome metabólica via inibição de hdac4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564031P | 2011-11-28 | 2011-11-28 | |
PCT/IB2012/056739 WO2013080120A1 (en) | 2011-11-28 | 2012-11-26 | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014012815A2 true BR112014012815A2 (pt) | 2017-06-13 |
BR112014012815A8 BR112014012815A8 (pt) | 2017-06-20 |
Family
ID=47428783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014012815A BR112014012815A8 (pt) | 2011-11-28 | 2012-11-26 | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
Country Status (11)
Country | Link |
---|---|
US (1) | US9670193B2 (pt) |
EP (1) | EP2785713B1 (pt) |
JP (1) | JP5966014B2 (pt) |
KR (1) | KR20140097459A (pt) |
AU (1) | AU2012345557A1 (pt) |
BR (1) | BR112014012815A8 (pt) |
CA (1) | CA2856334A1 (pt) |
EA (1) | EA201491060A1 (pt) |
ES (1) | ES2606630T3 (pt) |
MX (1) | MX2014006409A (pt) |
WO (1) | WO2013080120A1 (pt) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013008162A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
ES2729619T3 (es) * | 2013-11-20 | 2019-11-05 | Ohio State Innovation Foundation | Métodos para reprimir la caquexia relacionada con el cáncer |
CA3149871A1 (en) * | 2013-11-20 | 2015-05-28 | Ohio State Innovation Foundation | Methods for suppressing cancer-related cachexia |
EP3756464A1 (en) | 2014-06-06 | 2020-12-30 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
US10081624B2 (en) | 2014-08-26 | 2018-09-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2016179550A1 (en) * | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
WO2016179554A1 (en) * | 2015-05-07 | 2016-11-10 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
EP3302465A1 (en) | 2015-06-05 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
CA2992700A1 (en) * | 2015-07-17 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
JPWO2017014170A1 (ja) * | 2015-07-17 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
MX2018001193A (es) | 2015-07-27 | 2018-05-22 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. |
KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
MY190301A (en) * | 2015-07-27 | 2022-04-13 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
ES2903214T3 (es) | 2015-08-04 | 2022-03-31 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de la histona desacetilasa 6 y la composición farmacéutica que comprende los mismos |
JPWO2017033946A1 (ja) | 2015-08-25 | 2018-06-07 | 武田薬品工業株式会社 | 複素環化合物 |
MX2018003845A (es) | 2015-10-02 | 2018-06-18 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas. |
HUE050030T2 (hu) | 2015-10-02 | 2020-11-30 | Syngenta Participations Ag | Mikrobiocid oxadiazol-származékok |
KR101839137B1 (ko) * | 2015-10-12 | 2018-03-26 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
EP3165094A1 (en) | 2015-11-03 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
EP3165093A1 (en) | 2015-11-05 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
EP3167716A1 (en) | 2015-11-10 | 2017-05-17 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
AR106679A1 (es) | 2015-11-13 | 2018-02-07 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatógenos |
BR112018009566A2 (pt) | 2015-11-13 | 2018-11-06 | Basf Se | compostos, mistura, composição agroquímica, uso de compostos e método para combater fungos nocivos fitopatogênicos |
BR112018009539B1 (pt) | 2015-11-13 | 2022-05-24 | Basf Se | Uso de compostos da fórmula i, compostos, mistura, composição agroquímica, uso dos compostos e método para combater fungos nocivos fitopatogênicos |
CN108289449A (zh) | 2015-11-19 | 2018-07-17 | 巴斯夫欧洲公司 | 用于防除植物病原性真菌的取代噁二唑 |
UY36999A (es) | 2015-12-02 | 2017-06-30 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
MX2018006780A (es) | 2015-12-03 | 2018-08-01 | Basf Se | Oxadiazoles sustituidos para combatir hongos fitopatogenos. |
MX2021001091A (es) | 2015-12-10 | 2022-04-26 | Ptc Therapeutics Inc | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. |
UY37062A (es) | 2016-01-08 | 2017-08-31 | Syngenta Participations Ag | Derivados de aryl oxadiazol fungicidas |
BR112018069412B1 (pt) | 2016-03-24 | 2022-09-20 | Syngenta Participations Ag | Compostos derivados de oxadiazol microbiocidas, composição agroquímica, método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos e uso do referido composto |
WO2017178245A1 (en) | 2016-04-11 | 2017-10-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
WO2017222952A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
US11974572B2 (en) | 2017-03-31 | 2024-05-07 | Sygenta Participations Ag | Fungicidal compositions |
TW202417417A (zh) * | 2017-04-06 | 2024-05-01 | 美商富曼西公司 | 殺真菌之噁二唑 |
MX2019014514A (es) | 2017-06-05 | 2020-07-20 | Ptc Therapeutics Inc | Compuestos para tratar la enfermedad de huntington. |
CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
JP7135007B2 (ja) | 2017-07-31 | 2022-09-12 | 武田薬品工業株式会社 | 複素環化合物 |
CN111406054B (zh) * | 2017-12-05 | 2024-01-02 | 奥莱松基因组股份有限公司 | 作为组蛋白脱乙酰基酶6抑制剂的1,2,4-噁二唑衍生物 |
CR20200274A (es) | 2017-12-22 | 2020-08-13 | Bayer Cropscience Ag | Oxadiazoles fungicidas |
EP3752492B1 (en) | 2018-02-12 | 2022-12-21 | Bayer Aktiengesellschaft | Fungicidal oxadiazoles |
AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
AU2019252328A1 (en) | 2018-04-10 | 2020-10-22 | Bayer Aktiengesellschaft | Oxadiazoline derivatives |
EP4434990A1 (en) | 2018-06-27 | 2024-09-25 | PTC Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
US20220151234A1 (en) * | 2019-04-08 | 2022-05-19 | Pi Industries Ltd. | Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi |
EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
CA3142435A1 (en) * | 2019-06-06 | 2020-12-10 | Oryzon Genomics, S.A. | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors |
BR112021025300A2 (pt) | 2019-06-21 | 2022-02-01 | Bayer Ag | Oxadiazóis fungicidas |
MX2022003490A (es) | 2019-09-27 | 2022-04-25 | Takeda Pharmaceuticals Co | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6). |
WO2022129196A1 (en) | 2020-12-18 | 2022-06-23 | Bayer Aktiengesellschaft | Heterobicycle substituted 1,2,4-oxadiazoles as fungicides |
WO2022129188A1 (en) | 2020-12-18 | 2022-06-23 | Bayer Aktiengesellschaft | 1,2,4-oxadiazol-3-yl pyrimidines as fungicides |
WO2022129190A1 (en) | 2020-12-18 | 2022-06-23 | Bayer Aktiengesellschaft | (hetero)aryl substituted 1,2,4-oxadiazoles as fungicides |
BR112023019400A2 (pt) | 2021-03-30 | 2023-12-05 | Bayer Ag | 3-(hetero)aril-5-clorodifluorometil-1,2,4-oxadiazol como fungicida |
WO2022207496A1 (en) | 2021-03-30 | 2022-10-06 | Bayer Aktiengesellschaft | 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide |
MX2023012095A (es) | 2021-04-23 | 2023-12-14 | Tenaya Therapeutics Inc | Inhibidores de hdac6 para el uso en el tratamiento de la miocardiopatía dilatada. |
MX2023012875A (es) | 2021-05-04 | 2024-01-12 | Tenaya Therapeutics Inc | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. |
UY39854A (es) | 2021-07-15 | 2022-11-30 | Kumiai Chemical Industry Co | Derivado de formamida y agente de control hortícola y agrícola para el control de enfermedades de la |
WO2023078807A1 (en) | 2021-11-03 | 2023-05-11 | Universität Basel | A class iia hdac inhibitor and decitabine to treat myopathy |
WO2024068520A1 (en) | 2022-09-28 | 2024-04-04 | Bayer Aktiengesellschaft | 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide |
WO2024068518A1 (en) | 2022-09-28 | 2024-04-04 | Bayer Aktiengesellschaft | 3-heteroaryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide |
WO2024068519A1 (en) | 2022-09-28 | 2024-04-04 | Bayer Aktiengesellschaft | 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide |
WO2024068517A1 (en) | 2022-09-28 | 2024-04-04 | Bayer Aktiengesellschaft | 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole as fungicide |
EP4295688A1 (en) | 2022-09-28 | 2023-12-27 | Bayer Aktiengesellschaft | Active compound combination |
WO2024180464A1 (en) | 2023-02-28 | 2024-09-06 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole derivative compounds, and the pharmaceutical composition comprising the same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
KR20100107509A (ko) * | 2001-09-14 | 2010-10-05 | 9222-9129 퀘벡 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
KR100849747B1 (ko) | 2003-05-20 | 2008-07-31 | 노파르티스 아게 | 과산화소체 증식체-활성화 수용체의 리간드로서의 n-아실질소 헤테로환 |
WO2005040152A1 (en) | 2003-10-20 | 2005-05-06 | E.I. Dupont De Nemours And Company | Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides |
EP2044055A4 (en) | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
JP5718053B2 (ja) | 2007-08-27 | 2015-05-13 | ヘリコン・セラピューティクス・インコーポレーテッド | 治療用イソオキサゾール化合物 |
US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
JP6017313B2 (ja) * | 2010-01-13 | 2016-10-26 | テンペロ、ファーマシューティカルズ、インコーポレイテッドTempero Pharmaceuticals, Inc. | 化合物および方法 |
EP2523664A4 (en) | 2010-01-13 | 2013-06-26 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
JPWO2012011592A1 (ja) | 2010-07-23 | 2013-09-09 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2013008162A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
-
2012
- 2012-11-26 EP EP12805774.2A patent/EP2785713B1/en active Active
- 2012-11-26 MX MX2014006409A patent/MX2014006409A/es not_active Application Discontinuation
- 2012-11-26 WO PCT/IB2012/056739 patent/WO2013080120A1/en active Application Filing
- 2012-11-26 CA CA2856334A patent/CA2856334A1/en not_active Abandoned
- 2012-11-26 EA EA201491060A patent/EA201491060A1/ru unknown
- 2012-11-26 US US14/360,013 patent/US9670193B2/en active Active
- 2012-11-26 ES ES12805774.2T patent/ES2606630T3/es active Active
- 2012-11-26 KR KR1020147017436A patent/KR20140097459A/ko not_active Application Discontinuation
- 2012-11-26 AU AU2012345557A patent/AU2012345557A1/en not_active Abandoned
- 2012-11-26 BR BR112014012815A patent/BR112014012815A8/pt not_active Application Discontinuation
- 2012-11-26 JP JP2014542989A patent/JP5966014B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20140329825A1 (en) | 2014-11-06 |
MX2014006409A (es) | 2014-07-30 |
US9670193B2 (en) | 2017-06-06 |
AU2012345557A1 (en) | 2014-06-26 |
ES2606630T3 (es) | 2017-03-24 |
JP2014533721A (ja) | 2014-12-15 |
EA201491060A1 (ru) | 2014-09-30 |
WO2013080120A1 (en) | 2013-06-06 |
EP2785713A1 (en) | 2014-10-08 |
JP5966014B2 (ja) | 2016-08-10 |
BR112014012815A8 (pt) | 2017-06-20 |
EP2785713B1 (en) | 2016-09-07 |
KR20140097459A (ko) | 2014-08-06 |
CN103998446A (zh) | 2014-08-20 |
CA2856334A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
BR112014000371A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
BR112014008686A2 (pt) | derivados de oxazina e uso dos mesmos no tratamento de doença | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CY1118661T1 (el) | Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων | |
EA201490300A1 (ru) | 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов | |
MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
CU24117B1 (es) | Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica | |
EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
EA201001368A1 (ru) | Гетероциклические производные мочевины и способы их применения-211 | |
EA201391236A1 (ru) | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов | |
BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
GEP20156351B (en) | Glucagon receptor modulator | |
BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
BR112014015845A8 (pt) | derivados de azetidina, composições farmacêuticas e seu uso | |
EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
BR112015010396A2 (pt) | terapia de combinação | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
MX2013003635A (es) | Compuestos de n-heteroarilo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |